10 results about "Animal model" patented technology

The invention discloses an establishment method for a type 2 diabetes mellitus animal model. The establishment method comprises the following steps: (1) preparing a lipopolysaccharide solution with aconcentration of 100ug/ml by virtue of normal saline; (2) selecting male rats which are 4-6 weeks old, feeding by virtue of a common feed, and simultaneously injecting the lipopolysaccharide solution;(3) weighing the male rats after 28 days; (4) after the weighing, fasting for 8 hours, separating serum, and measuring blood glucose and insulin; (5) evaluating the resistance of the insulin and glucose stimulated insulin secretion capacity; (6) respectively intraperitoneally injecting an STZ solution into the male rats in the 30th day and the 32th day; and (7) determining that the establishmentof the type 2 diabetes mellitus animal model is finished when the random blood sugar is more than 16.8mmol/L. According to the establishment method, lipopolysaccharide in Escherichia coli 0111:B4 subspecies is selected and is matched with the feeding of the common feed and the STZ injection so as to successfully establish the type 2 diabetes mellitus animal mode; according to the establishment method, the operation is easy, the model establishment cost is low, the model establishment rate is high, and the model establishment period is short.

The invention relates to a method for establishing an animal model for senile dementia, a special liquid medicine and a dosing device, and belongs to the technical field of neurosciences. The method comprises the following steps: obtaining positioning coordinates of paraceles according to brain atlases or/and magnetic resonance image data of an experimental animal; respectively burying a conduit of the dosing device in left and right paraceles of the animal, and injecting the special liquid medicine to the paraceles at a constant speed in 14-16 minutes under a sterile environment within 2-3 weeks, wherein the liquid medicine amount is 100-250 ml methanol per day; alternately dosing the left and right paraceles, wherein the dosing frequency is 18-30 hours at an interval; and continuously dosing for 2-10 months to obtain a non-human primate animal model for senile dementia. With the adoption of a novel dosing mode: dosing to the paraceles at the constant speed, medicine can circulate to whole brain through the cerebrospinal fluid to exert the toxic effect, so that peripheral damage by the medicine is avoided. The AD model is established by injecting methanol or formaldehyde to the paraceles, so that behaviors and pathological symptoms are typical, the basic physiological status is good and the individual difference is relatively smaller.

The invention provides a method for manufacturing a transcranial high-voltage electricity burning animal model, which comprises steps: skin preparation, anesthesia, fixation and electric shocking. According to the invention, the successful rate of the transcranial high-voltage electricity burning animal model manufactured by the method provided herein is high; and an inlet and an outlet of the model are clear.

The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).

The invention relates to a preparation method of an in vivo glycation level-improving dementia animal model. By dosing animals with D-ribose, the invention provides an in vivo glycation level-improving dementia animal model and its preparation method. The animal model provided in the invention has the characteristics of normal blood sugar level, enhanced glycation level, and damaged spatial learning and memory ability. At the same time, the method disclosed in the invention has the advantages of simplicity, practicability, easy control, stability and good reproducibility, low model making cost as well as short model making cycle. The model making method provided in the invention can be used for qualitative and quantitative analysis, pathomorphological contrastive analysis, and also can be used for statistical treatment and analysis. Also, the method can be used for studying in vivo glycation level enhancement-caused related diseases and the pathogenesis of neurodegenerative diseases, as well as studying and evaluating related disease treatment methods.

The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.

Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

The invention discloses a sarcopenia animal model establishing method. The method comprises the following steps of purchasing 4-week-old male mice, and feeding the 4-week-old male mice in different cages; measuring the body weight, body composition and muscle function of male mice once in pairs every month from the age of 1 month, randomly selecting three mice, performing intraperitoneal injectionof 7% chloral hydrate solution for anesthesia, taking out skeletal muscles of lower limbs, weighing, preparing a frozen specimen, transferring the frozen specimen into a refrigerator at the temperature of -80 DEG C, and storing for later use; fixedly observing and recording mice muscle function measurement results every month, and regarding that modeling is successful when a month mean value of the mice muscle function measurement results is reduced. The experimental difficulty, experimental conditions, economical efficiency and the like of the method are greatly improved compared with thoseof an existing model, an animal model which is stable, good in repeatability and closer to clinic in mechanism can be provided, and a good animal model sample is provided for studying the molecular mechanism, the pathophysiological characteristics and drug research and development of the sarcopenia.

The invention relates to the technical field of epilepsy model construction, in particular to a new method for inducing epilepsy models through drugs, namely a new application method of a pharmacological tool drug. The epilepsy models are induced in vivo and in vitro. KN93 serves as the pharmacological tool drug to be applied to building and inducing the epilepsy animal model and the epilepsy cellmodel. The KN93 in the method can simultaneously induce the epilepsy animal model and the epilepsy cell model, and an epilepsy model caused by drugs in the prior art is one of an animal model (in vivo) and a cell model (in vitro), and therefore the KN93 can induce the epilepsy models in vivo and in vitro; then an epilepsy disease mechanism is deeply discussed and related anti-epileptic drugs arescreened.